Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.

Molecular biology reports - 1 Feb 2011

Herreros-Villanueva Marta, Rodrigo Maximiliano, Claver Manuel, Muñiz Pilar, Lastra Enrique, García-Girón Carlos, Coma del Corral Maria Jesus

Abstract excerpt

To evaluate the KRAS, BRAF, EGFR, and HER2 gene status in colorectal cancer by novel techniques and evaluate whether anti-HER2 therapies could be offered in the treatment of these patients. There are conflicting data on the prevalence of BRAF mutations and EGFR and HER2 gene amplification in colorectal KRAS wild type patients. In our study we tried to evaluate these expressions and their relationship to future...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Expression Regulation, Neoplastic

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 20563851
DOI: 10.1007/s11033-010-0232-x

Genes

KRAS
BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.PMID 20563851Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.Semantic proximity Read ↗

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancerSemantic proximity Read ↗

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.Semantic proximity Read ↗

A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer.Semantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.Semantic proximity Read ↗

Different Clinicopathological Characteristics in Indonesian Colorectal Patients with NRAS Mutations and HER2 Over-Expression.Semantic proximity Read ↗

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.Semantic proximity Read ↗

[Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.